The 6 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 6.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +360.99% increase from the last price of 1.41.
The current consensus among 7 polled investment analysts is to Buy stock in Nabriva Therapeutics PLC. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.33
Reporting Date Mar 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.